FIELD: pharmaceuticals.
SUBSTANCE: invention relates to a method for treatment or prevention of cell proliferation disorders in KRAS-mutant and/or NRAS-mutant cancer, including (a) administering a potassium salt of the compound represented by the formula (I) twice a week for 3 weeks in a dose of 3.2 or 4 mg per administration, (b) suspending administration of said salt for the next 1 week, and (c) consecutively repeating the stages (a) and (b) at least once.
EFFECT: described method provides a possibility of reducing the side effects in the form of a rash in patients receiving a medicinal product containing a compound by the formula (I).
14 cl, 1 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS AND MEDICAL APPLICATIONS | 2018 |
|
RU2788163C2 |
| METHODS AND MEDICAL APPLICATIONS | 2018 |
|
RU2788174C2 |
| COMBINATION THERAPY | 2018 |
|
RU2815400C2 |
| THERAPEUTIC COMBINATIONS CONTAINING RAF INHIBITOR AND ERK INHIBITOR | 2017 |
|
RU2774612C2 |
| METHODS OF EX VIVO EXPANSION OF NATURAL KILLER CELLS AND THEIR USE | 2019 |
|
RU2814083C2 |
| MUTANT SELECTIVITY AND COMBINATIONS OF A PHOSPHOINOSITIDE-3-KINASE INHIBITOR COMPOUND AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER | 2013 |
|
RU2665949C2 |
| COMPOSITIONS COMPRISING CD38 ANTIBODIES AND CARFILZOMIB | 2014 |
|
RU2723937C2 |
| COMBINATIONS OF INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE AND CHEMIOTHERAPEUTIC AGENTS AND METHODS OF APPLICATION | 2008 |
|
RU2523890C2 |
| COMBINATION THERAPY | 2013 |
|
RU2677245C2 |
| METHOD OF TREATING CANCER ASSOCIATED WITH A RAS MUTATION | 2016 |
|
RU2736045C2 |
